Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Characterization of a liposomal copper(II)-quercetin formulation suitable for parenteral use.

Chen KTJ, Anantha M, Leung AWY, Kulkarni JA, Militao GGC, Wehbe M, Sutherland B, Cullis PR, Bally MB.

Drug Deliv Transl Res. 2019 Sep 3. doi: 10.1007/s13346-019-00674-7. [Epub ahead of print]

PMID:
31482519
2.

Recent Treatment Advances and the Role of Nanotechnology, Combination Products, and Immunotherapy in Changing the Therapeutic Landscape of Acute Myeloid Leukemia.

Chen KTJ, Gilabert-Oriol R, Bally MB, Leung AWY.

Pharm Res. 2019 Jun 24;36(9):125. doi: 10.1007/s11095-019-2654-z. Review.

3.

What Drives Innovation: The Canadian Touch on Liposomal Therapeutics.

Leung AWY, Amador C, Wang LC, Mody UV, Bally MB.

Pharmaceutics. 2019 Mar 16;11(3). pii: E124. doi: 10.3390/pharmaceutics11030124. Review.

4.

Liposomal Formulations to Modulate the Tumour Microenvironment and Antitumour Immune Response.

Gilabert-Oriol R, Ryan GM, Leung AWY, Firmino NS, Bennewith KL, Bally MB.

Int J Mol Sci. 2018 Sep 26;19(10). pii: E2922. doi: 10.3390/ijms19102922. Review.

5.

Copper-CX-5461: A novel liposomal formulation for a small molecule rRNA synthesis inhibitor.

Leung AWY, Anantha M, Dragowska WH, Wehbe M, Bally MB.

J Control Release. 2018 Sep 28;286:1-9. doi: 10.1016/j.jconrel.2018.07.025. Epub 2018 Jul 18.

6.

Transition Metal Ions Promote the Bioavailability of Hydrophobic Therapeutics: Cu and Zn Interactions with RNA Polymerase I Inhibitor CX5461.

Prosser KE, Leung AWY, Harrypersad S, Lewis AR, Bally MB, Walsby CJ.

Chemistry. 2018 Apr 25;24(24):6334-6338. doi: 10.1002/chem.201800289. Epub 2018 Apr 6.

PMID:
29490115
7.

In Vivo Validation of PAPSS1 (3'-phosphoadenosine 5'-phosphosulfate synthase 1) as a Cisplatin-sensitizing Therapeutic Target.

Leung AWY, Veinotte CJ, Melong N, Oh MH, Chen K, Enfield KSS, Backstrom I, Warburton C, Yapp D, Berman JN, Bally MB, Lockwood WW.

Clin Cancer Res. 2017 Nov 1;23(21):6555-6566. doi: 10.1158/1078-0432.CCR-17-0700. Epub 2017 Aug 8.

8.

Copper (II) complexes of bidentate ligands exhibit potent anti-cancer activity regardless of platinum sensitivity status.

Wehbe M, Lo C, Leung AWY, Dragowska WH, Ryan GM, Bally MB.

Invest New Drugs. 2017 Dec;35(6):682-690. doi: 10.1007/s10637-017-0488-2. Epub 2017 Jul 21.

9.

A Perspective - can copper complexes be developed as a novel class of therapeutics?

Wehbe M, Leung AWY, Abrams MJ, Orvig C, Bally MB.

Dalton Trans. 2017 Aug 22;46(33):10758-10773. doi: 10.1039/c7dt01955f. Review.

PMID:
28702645
10.

A simple passive equilibration method for loading carboplatin into pre-formed liposomes incubated with ethanol as a temperature dependent permeability enhancer.

Wehbe M, Malhotra A, Anantha M, Roosendaal J, Leung AWY, Plackett D, Edwards K, Gilabert-Oriol R, Bally MB.

J Control Release. 2017 Apr 28;252:50-61. doi: 10.1016/j.jconrel.2017.03.010. Epub 2017 Mar 10.

11.

Synthetic lethality in lung cancer and translation to clinical therapies.

Leung AW, de Silva T, Bally MB, Lockwood WW.

Mol Cancer. 2016 Sep 29;15(1):61. Review.

12.

Sulfonation, an underexploited area: from skeletal development to infectious diseases and cancer.

Leung AW, Backstrom I, Bally MB.

Oncotarget. 2016 Aug 23;7(34):55811-55827. doi: 10.18632/oncotarget.10046. Review.

13.

Combined Use of Gene Expression Modeling and siRNA Screening Identifies Genes and Pathways Which Enhance the Activity of Cisplatin When Added at No Effect Levels to Non-Small Cell Lung Cancer Cells In Vitro.

Leung AW, Hung SS, Backstrom I, Ricaurte D, Kwok B, Poon S, McKinney S, Segovia R, Rawji J, Qadir MA, Aparicio S, Stirling PC, Steidl C, Bally MB.

PLoS One. 2016 Mar 3;11(3):e0150675. doi: 10.1371/journal.pone.0150675. eCollection 2016.

14.

Induction of Cytotoxicity in Pyridine Analogues of the Anti-metastatic Ru(III) Complex NAMI-A by Ferrocene Functionalization.

Mu C, Chang SW, Prosser KE, Leung AW, Santacruz S, Jang T, Thompson JR, Yapp DT, Warren JJ, Bally MB, Beischlag TV, Walsby CJ.

Inorg Chem. 2016 Jan 4;55(1):177-90. doi: 10.1021/acs.inorgchem.5b02109. Epub 2015 Dec 11.

PMID:
26652771
15.

3'-Phosphoadenosine 5'-phosphosulfate synthase 1 (PAPSS1) knockdown sensitizes non-small cell lung cancer cells to DNA damaging agents.

Leung AW, Dragowska WH, Ricaurte D, Kwok B, Mathew V, Roosendaal J, Ahluwalia A, Warburton C, Laskin JJ, Stirling PC, Qadir MA, Bally MB.

Oncotarget. 2015 Jul 10;6(19):17161-77.

16.

Harnessing the potential of lipid-based nanomedicines for type-specific ovarian cancer treatments.

Leung AW, Kalra J, Santos ND, Bally MB, Anglesio MS.

Nanomedicine (Lond). 2014 Mar;9(3):501-22. doi: 10.2217/nnm.13.220. Review.

PMID:
24746193
17.

Contributions of conserved residues at the gating interface of glycine receptors.

Pless SA, Leung AW, Galpin JD, Ahern CA.

J Biol Chem. 2011 Oct 7;286(40):35129-36. doi: 10.1074/jbc.M111.269027. Epub 2011 Aug 11.

Supplemental Content

Loading ...
Support Center